P. Andrew Futreal
University of Texas MD Anderson Cancer Center
350 Papers
1K Citations
P. Andrew Futreal is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 107, co-authored 245 publications. Previous affiliations of P. Andrew Futreal include Wellcome Trust & Wellcome Trust Sanger Institute.
Chat about Author
Papers
1498 Deploying spatial transcriptomics to inform on intratumoral heterogeneity in late-stage uveal melanoma leveraging advanced preclinical modeling and clinical samples
Sanjana Srinivasan,Johnathon L. Rose,Joseph R Daniele,Michael Peoples,Meng He,Rosalba Minelli,Christopher Terranova,Chiu Yi Liu,Jason Gay,Melinda Soeung,Khalida M Wani,Luigi Perelli,Dmitry Loza,Ningping Feng,Christopher P. Vellano,Joseph Marszalek,Giulio F. Draetta,P. Andrew Futreal,Scott Woodman,Alexander J Lazar,Timothy Heffernan,Alessandro Carugo,Giannicola Genovese,Virginia Giuliani +23 more
- 31 Oct 2023
TL;DR: This study leverages spatial transcriptomics and preclinical modeling to investigate intratumoral heterogeneity in late-stage uveal melanoma, particularly in monosomy 3 tumors, and identifies unique gene signatures and microenvironmental features associated with disease progression and metastasis.
Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups
Sanghoon Lee,Li Zhao,Latasha Little,Shannon N. Westin,Amir A. Jazarei,Nicole D. Fleming,Jianhua Zhang,P. Andrew Futreal,Anil K. Sood +8 more
TL;DR: In this paper, the authors evaluated T-cell receptor (TCR) repertoire diversity in primary and metastatic tumor samples (n = 90) from clinically well-annotated patients with serous ovarian cancer who achieved R0 or received NACT with excellent or poor response based on a laparoscopic triage algorithm.
Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors
Kwong Kwok Wong,D. Nicholas Bateman,Chun Wai. Ng,Yvonne T.M. Tsang,Chong-Son Sun,Joseph Celestino,Tri H. Nguyen,Anais Malpica,R. Tyler Hillman,Jianhua Zhang,P. Andrew Futreal,Christina R. Rojas,Kelly A. Conrads,Brian L. Hood,Clifton L. Dalgard,Matthew D. Wilkerson,Neil T. Phippen,Thomas P. Conrads,G. Larry Maxwell,Anil K. Sood,David M. Gershenson +20 more
TL;DR: In this paper , the authors compared the proteogenomic analyses of low grade serous ovarian cancer (LGSOC) from short and long-term survivors (defined as < 40 and > 60 months, respectively).
•Journal Article
Mutation of the PTEN Tumor Suppressor Gene in Endometrial Hyperplasias
G. Larry Maxwell,John I. Risinger,Curtis Gumbs,Heather S. Shaw,Rex C. Bentley,J. Carl Barrett,Andrew Berchuck,P. Andrew Futreal +7 more
TL;DR: The data suggest that inactivation of the PTEN tumor suppressor gene is an early event in the development of some endometrial cancers.
Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS
Jing Wang,Yuting Yi,Yi Xiao,Lin Dong,Li Liang,Lianghong Teng,Jian Ming Ying,Tao Lu,Yuanyuan Liu,Yanfang Guan,Junyi Pang,Lianrui Zhou,Junliang Lu,Zhiwen Zhang,Xiaoding Liu,Xiaolong Liang,Xuan Zeng,Xin Yi,Weixun Zhou,Xuefeng Xia,Ling Yang,Jianjun Zhang,Scott Kopetz,P. Andrew Futreal,Huanwen Wu,Zhiyong Liang +25 more
TL;DR: Oncogenic fusions were highly enriched and frequently detected in mismatch repair-deficient colorectal carcinomas with MLH1 hypermethylation and wild-type BRAF and KRAS, and were associated with poor prognosis and high tumor CD274(PD-L1) expression.